Bio-Techne
$72.40Change from previous close: 0.00%
At a glance
- Revenue growth
- −0.38%
- FY to Jun 2026 vs FY to Jun 2025
- Net income growth
- +147.77%
- FY to Jun 2026 vs FY to Jun 2025
- Net margin
- 15.0%
- FY to Jun 2025: 6.0%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | FY to Jun 2026 | FY to Jun 2025 | FY to Jun 2024 | FY to Jun 2023 | FY to Jun 2022 |
|---|---|---|---|---|---|
| Operating cash flow | 292 | 288 | 299 | 254 | — |
| Depreciation and amortization | 97.4 | 110 | 112 | 107 | — |
| Capital expenditure | -28.9 | -31.0 | -62.9 | -38.2 | — |
| Investing cash flow | -18.2 | -35.2 | -203 | -266 | — |
| Financing cash flow | -169 | -254 | -122 | 22.6 | — |
| Dividends paid | -49.9 | -50.4 | -50.4 | -50.3 | — |
| Share repurchases | -41.7 | -276 | -80.0 | -19.6 | — |
| Debt issued | 0.0 | 104 | 225 | 620 | — |
| Debt repaid | -146 | -77.0 | -256 | -526 | — |
| Effect of exchange rates | -2.2 | 11.9 | -2.3 | -3.4 | — |
| Net change in cash | 105 | -1.5 | -26.4 | 11.4 | — |
| Free cash flow | 263 | 257 | 236 | 216 | — |